Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Elena Vega

IgA Nephropathy Patients on Trutakna Kept Kidney Function Nearly Steady for Two Years While Placebo Group Declined

Adults with IgA nephropathy who took Trutakna (atacicept-vymj) lost an average of 0.6 units of estimated kidney function per year over two years, while those on placebo lost 5.6 units per year, Vera Therapeutics reported on Sept. 15. The results come from the final efficacy analysis of the 428-patient ORIGIN 3 trial.

Update Note: This article reports new two-year kidney function results for Trutakna following MedicalDaily's earlier coverage of the drug's July approval. The latest verified information comes from a Vera Therapeutics announcement dated Sept. 15, 2026, and reflects topline data from the ORIGIN 3 final efficacy analysis.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.